PD-L1 expression on TANs was reported in several cancers, such as head and neck squamous cell carcinoma, hepatocellular carcinoma, colon cancer, gastric cancer, and lung cancer, and may constitute targets for anti-immune checkpoint treatments [55]. This evidence concerns the gene CD274 and cancer.